{"id":"CU22225","slug":"pamam-nanoparticle-for--CU22225","source":{"id":"CU22225","dataset":"techtransfer","title":"PAMAM nanoparticle for chemotherapy delivery to reduce metastasis and cognitive impairment","description_":"<p>This technology is a nanoparticle delivery system functionalized with cationic polymers that delivers chemotherapeutics and scavenges cell-free nucleic acids to reduce inflammation, metastasis, and cognitive impairment.</p>\r\r<h2>Unmet Need: Chemotherapy-induced metastasis and persistent cognitive impairment</h2>\r\r<p>Chemotherapeutic drugs such as paclitaxel and doxorubicin treat primary breast tumors but can trigger the release of cell-free nucleic acids (cfNAs) from damaged cells. These cfNAs drive chronic inflammation, contributing to tumor metastasis and long-term cognitive impairment following treatment. As a result, patients may experience persistent neurological side effects despite initial therapeutic success. </p>\r\r<h2>The Technology: PAMAM nanoparticles designed to simultaneously treat primary tumors and prevent chemotherapy-induced metastasis and cognitive impairment</h2>\r\r<p>This technology is a nanoparticle delivery system made of cholesterol-modified cationic polyamidoamine (PAMAM) dendrimers that bind and scavenge cell-free nucleic acids (cfNAs). These polymeric materials self-assemble into size-controlled nanoparticles that deliver chemotherapeutics while simultaneously neutralizing cfNAs. By reducing cfNA-driven systemic inflammation, this approach limits chemotherapy-associated metastasis and cognitive impairment while maintaining anti-tumor efficacy. </p>\r\r<p>This technology has been validated for both antitumor efficacy and for treating cognitive impairment in an NSG mouse model and Balb/c mouse model, respectively. </p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Chemotherapeutic to inhibit early-stage and metastatic tumors </li>\r<li>Alleviates chemotherapy-induced cognitive impairment </li>\r<li>Scavenges inflammatory cell-free nucleic acids  </li>\r<li>Drug delivery platform for inflammatory diseases </li>\r<li>Research model for drug delivery </li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Simultaneously treats cancer and harmful side effects of systemic inflammation </li>\r<li>Inhibits chemotherapy-induced metastasis </li>\r<li>Prevents long-term cognitive impairment </li>\r<li>Flexible platform for other inflammatory diseases </li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://leonglab.bme.columbia.edu/people/kam-w-leong-phd\">Kam W. Leong, Ph.D.</a> </p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending (<a href=\"https://patents.google.com/patent/US20250090489A1/en?oq=US18%2f970%2c049\">WO/2025/0090489</a>) </p>\r\r<h2>Related Publications:</h2>\r\r<ul>\r<li><a href=\"https://pubmed.ncbi.nlm.nih.gov/36220339/\">Li T, Akinade T, Zhou J, Wang H, Tong Q, He S, Rinebold E, Valencia Salazar LE, Bhansali D, Zhong Y, Ruan J, Du J, Dalerba P, Leong KW. “Therapeutic Nanocarriers Inhibit Chemotherapy-Induced Breast Cancer Metastasis.” Adv Sci. 2022 Nov;9(33):e2203949.</a> </li>\r</ul>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU22225, CU19240, CU22070</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Dovina Qu</a></p></li>\r</ul>\r","tags":["Breast cancer","Chemotherapy","Cognitive deficit","Dendrimer","Doxorubicin","Drug delivery","Inflammation","Metastasis","Nanoparticle","Nucleic acid","Paclitaxel"],"file_number":"CU22225","collections":[],"meta_description":"PAMAM nanoparticles deliver chemotherapy while scavenging cell-free nucleic acids to reduce metastasis and cognitive impairment.","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":4.0,\"timeliness\":3.0},\"weighted_score\":3.9,\"risks\":[\"Assay translation to humans unproven; NSG/Balb/c strains limit immune relevance\",\"Safety and toxicity of PAMAM dendrimers in humans uncertain\",\"Manufacturing/regulatory challenges for complex multifunctional nanoparticles\",\"Potential competition with existing cfNA-targeting approaches\",\"IP landscape and patent status; dependence on ongoing patent-pending protection\"],\"one_sentence_take\":\"Multifunctional, self-assembling PAMAM nanoparticles offer a promising dual drug-delivery and cfNA-neutralizing approach with strong preclinical signals, but translation to humans and scalable manufacturing pose notable risks.\"}","inventors":["Divya Bhansali","Hongxia Wang","Kam Leong","Tianyu Li","Tolulope Akinade"],"manager":"Dovina Qu","depts":["Biomedical Engineering"],"divs":["Fu Foundation School of Engineering and Applied Science (SEAS)"],"date_released":"2026-04-24"},"highlight":{},"matched_queries":null,"score":0.0}